# Tissue-Derived Small Extracellular Vesicles: Emerging Regulators of Inter-Organ Crosstalk in Health and Disease

**Authors:** Yin-Qiong Huang, Chuan-Yu Zhong, George Burley, Yan-Chuan Shi, Shu Lin

PMC · DOI: 10.3390/metabo16030148 · 2026-02-24

## TL;DR

Tiny cell messengers called sEVs help organs talk to each other and may play a role in diseases like brain disorders and cancer.

## Contribution

This review highlights cross-tissue and cross-disease roles of sEVs and introduces the idea of sEVs as a third communication pathway between the brain and body.

## Key findings

- sEVs are involved in neurological, metabolic, cardiovascular, and bone diseases through inter-organ communication.
- CNS-derived sEVs may act as a new communication pathway alongside neurons and hormones.
- Standardized methods for studying sEVs are needed for clinical applications.

## Abstract

Small extracellular vesicles (sEVs; commonly referred to as “exosomes” in many studies) are nanoscopic messengers released by healthy and diseased cells that mediate intercellular communication by transferring proteins, lipids, and nucleic acids to local or distant recipient cells. In this narrative review, we synthesize recent evidence linking tissue-derived sEVs to neurological disorders (including neurodegeneration and traumatic brain injury), metabolic syndrome, cardiovascular diseases, cancers, and bone diseases, with a particular emphasis on CNS–periphery crosstalk across the blood–brain barrier. Compared with prior reviews that focus on single organ systems, we highlight cross-disease, cross-tissue mechanisms and summarize candidate biomarker cargos and therapeutic strategies in dedicated tables. While accumulating data support brain–body communication via sEVs, the concept of CNS-derived sEVs acting as a “third central efferent pathway” is presented here as an emerging hypothesis that complements—rather than replaces—neuronal and endocrine signaling. Overall, tissue-derived sEVs represent a promising but still evolving platform for diagnostic and therapeutic innovation, warranting standardized isolation/characterization and further clinical validation.

## Linked entities

- **Diseases:** traumatic brain injury (MONDO:0858950), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Genes:** Ppargc1a (peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) [NCBI Gene 19017] {aka A830037N07Rik, Gm11133, PGC-1, PPARGC-1-alpha, Pgc-1alpha, Pgc1}, Mir9-3 (microRNA 9-3) [NCBI Gene 723968] {aka Mirn9-3, mir-9-3, mmu-mir-9-3}, HOTAIR (HOX transcript antisense RNA) [NCBI Gene 100124700] {aka HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072}, Mir155 (microRNA 155) [NCBI Gene 387173] {aka Mirn155, mir-155, mmu-mir-155}, MIR204 (microRNA 204) [NCBI Gene 406987] {aka MIRN204, RDICC, miRNA204, mir-204}, Snca (synuclein, alpha) [NCBI Gene 20617] {aka NACP, alpha-Syn, alphaSYN}, Mir146 (microRNA 146) [NCBI Gene 387164] {aka Mirn146, miR-146a, mmu-mir-146}, Mir215 (microRNA 215) [NCBI Gene 387211] {aka Mirn215, mir-215, mmu-mir-215}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, GPM6A (glycoprotein M6A) [NCBI Gene 2823] {aka GPM6, M6A}, Mir126a (microRNA 126a) [NCBI Gene 387145] {aka Mir126, Mirn126, mir-126a, mmu-mir-126, mmu-mir-126a}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, Mir27a (microRNA 27a) [NCBI Gene 387220] {aka Mirn27a, mir-27a, mmu-mir-27a}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, Igf2 (insulin-like growth factor 2) [NCBI Gene 16002] {aka Igf-2, Igf-II, M6pr, Mpr, Peg2}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, Satb2 (special AT-rich sequence binding protein 2) [NCBI Gene 212712] {aka BAP002, mKIAA1034}, Bdnf (brain derived neurotrophic factor) [NCBI Gene 12064], Mir21a (microRNA 21a) [NCBI Gene 387140] {aka Mir21, Mirn21, mmu-mir-21, mmu-mir-21a}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, Uchl1 (ubiquitin carboxy-terminal hydrolase L1) [NCBI Gene 22223] {aka PGP 9.5, PGP9.5, UCH-L1, UCHL-1, gad}, Malat1 (metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA)) [NCBI Gene 72289] {aka 2210401K01Rik, 9430072K23Rik, Neat2}, Mir124a-3 (microRNA 124a-3) [NCBI Gene 723951] {aka Mirn124a-3, mir-124-3, mir-124a-3}, SNAP23 (synaptosome associated protein 23) [NCBI Gene 8773] {aka HsT17016, SNAP-23, SNAP23A, SNAP23B}, Mir34c (microRNA 34c) [NCBI Gene 723932] {aka Mirn34c, mir-34c, mmu-mir-34c}, Fndc5 (fibronectin type III domain containing 5) [NCBI Gene 384061] {aka 1500001L03Rik, PeP, Pxp}, RAB35 (RAB35, member RAS oncogene family) [NCBI Gene 11021] {aka H-ray, RAB1C, RAY}, Ctsb (cathepsin B) [NCBI Gene 13030] {aka APPM, CB}, Mir34a (microRNA 34a) [NCBI Gene 723848] {aka Mirn34a, mir-34a, mmu-mir-34a}
- **Diseases:** synucleinopathy (MESH:D000080874), Neoplastic Diseases (MESH:D004194), cardiac hypertrophy (MESH:D006332), metastasis (MESH:D009362), NASH (MESH:D005235), Bone Diseases (MESH:D001847), Lung Cancer (MESH:D008175), osteoporotic (MESH:D058866), NAFLD (MESH:D065626), type 2 diabetes (MESH:D003924), obese (MESH:D009765), vascular complications (MESH:D003925), dyslipidemia (MESH:D050171), stroke (MESH:D020521), synaptic injury (MESH:D012183), metabolic dysregulation (MESH:D021081), injury to (MESH:D014947), insulin resistance (MESH:D007333), Atherosclerosis (MESH:D050197), diabetes (MESH:D003920), Ovarian and Breast Cancer (MESH:D061325), OA (MESH:D010003), cardiovascular, oncological, and musculoskeletal disorders (MESH:D009139), Neurodegenerative Diseases (MESH:D019636), pain (MESH:D010146), CVD (MESH:D002318), NSCLC (MESH:D002289), PD (MESH:D010300), cognitive decline (MESH:D003072), neurotoxic (MESH:D020258), HCC (MESH:D006528), Neuroinflammation (MESH:D000090862), hypoxia (MESH:D000860), brain dysfunction (MESH:D001927), cardiac fibrosis (MESH:D005355), multiple sclerosis (MESH:D009103), HCC tumours (MESH:D009369), hypertrophic (MESH:D002312), joint pain (MESH:D018771), cartilage degeneration (MESH:D002357), AMI (MESH:D009203), metabolic abnormalities (MESH:D008659), neuronal injury (MESH:D009410), TBI (MESH:D000070642), ovarian cancer (MESH:D010051), ischemic injury (MESH:D017202), adipose dysfunction (MESH:D018205), arrhythmias (MESH:D001145), fracture (MESH:D050723), inflammation (MESH:D007249), OSA (MESH:D020181), hyperglycemia (MESH:D006943), Heart Failure (MESH:D006333), neurological disorders (MESH:D009461), Osteoporosis (MESH:D010024), skeletal disorder (MESH:C564967), hypoxic (MESH:D002534), breast cancer (MESH:D001943), hypertension (MESH:D006973), AD (MESH:D000544)
- **Chemicals:** 2-DG (MESH:D003847), Antagomir-188 (-), lipid (MESH:D008055), glucose (MESH:D005947)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027838/full.md

---
Source: https://tomesphere.com/paper/PMC13027838